AN2 Therapeutics, Inc. (Nasdaq: ANTX) has announced a collaboration with the Drugs for Neglected Diseases initiative (DNDi) to advance the clinical development of AN2-502998, an oral drug candidate for the treatment of chronic Chagas disease. This partnership aims to leverage DNDi's extensive expertise in Chagas disease clinical trials, enhancing resource optimization and scientific execution. The initiative is part of DNDi's broader pipeline focused on novel treatments for Chagas disease. The collaboration will also include biomarker research and implementation studies to ensure effective diagnostics and treatments reach the patients in need. Results of the ongoing development have not yet been presented.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。